Vericiguat: The Fifth Pillar of Heart Failure.

Rev Cardiovasc Med · 2026 · PMC13339232 · PMID 42416584

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The VICTOR trial was neutral for the primary endpoint, but its nominally significant mortality benefit made it consistent with the signal observed in the pooled analysis [ 6 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.